Videos

Key points to remember when performing cardiac ablations in ASCs
When CMS finalized coverage for cardiac ablations performed in ASCs, experts from HRS and ACC published recommendations for performing those procedures safely and effectively. One of the cardiologists behind that guidance shared some important takeaways with Cardiovascular Business.
ASNC speaks to policymakers about prior authorization, Medicare cuts and more
The American Society of Nuclear Cardiology visited Capitol Hill to advocate for a variety of issues. Cardiovascular Business spoke to the group's president to learn more.
AATS helps heart surgeons diagnose and manage heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia after heart surgery is a major concern, but prior guidelines were developed without much feedback from actual cardiac surgeons.
Upfront costs of robotic heart surgery are high—but it may be a smart investment
Makoto Hashimoto, MD, PhD, said robotic procedures are associated with a faster recovery time and many other potential benefits.
Resilia tissue developed by Edwards Lifesciences associated with long-term durability
Kevin Accola, MD, spoke to Cardiovascular Business about new 10-year data on the performance of surgical valves featuring Resilia tissue. The findings are good news for Edwards Lifesciences, which also includes the tissue on many of its TAVR devices.

Deepak Bhatt discusses the MOMENTUM STUDY and the prevalence of hypercortisolism hypertension. #ACC #ACC26

New data highlight an unexpected link between hypercortisolism and resistant hypertension

Clinicians may need to broaden their diagnostic approach when treating and managing patients with resistant hypertension.

William P. Shutze, MD, FACS, secretary of the Society of Vascular Surgery (SVS), a vascular surgeon with Texas Vascular Associates in Plano, Texas, and a clinical associate professor of medicine at Texas A&M College of Medicine, explains the goals of the SVS quality assessment program.

SVS quality initiative gathers data to improve vascular care

More than 7,000 physicians from a wide variety of healthcare specialties are already participating in the project.

Video interview with Ronald Crystal, MD, chair, Department of Genetic Medicine at Weill Cornell Medicine, presented late-breaking findings on a first in-human, virus-delivered gene therapy trial to stop cardiomyopathy death in patients with Friedreich Ataxia (FA). #ACC #ACC26

New gene therapy may help protect the hearts of patients with Friedreich's ataxia

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Getting vascular surgeons more involved leads to key improvements for PAD patients

Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?

Videos

Key points to remember when performing cardiac ablations in ASCs

ASNC speaks to policymakers about prior authorization, Medicare cuts and more

AATS helps heart surgeons diagnose and manage heparin-induced thrombocytopenia

Upfront costs of robotic heart surgery are high—but it may be a smart investment

Resilia tissue developed by Edwards Lifesciences associated with long-term durability